Saturday, November 22, 2025 7:43:43 PM
Snug, I encourage to let go of an RS and uplist. We've been told multiple times that was absolute last option. He has literally said that multiple times. Please don't be like the village idiot $2 fake king who thinks that's happening. He literally told us he gave the team until end of year to determine if M&A was a viable option and then proceeded to say "and it looks like it is". He also said that in a very upbeat manner. Go listen to how he says that on the call. Then went on to discuss unsolicited company who came for a tour and a handful of other companies that might be in play. So unless you think he's lying about the unsolicited company stopping by and/or the list the consultants have lined up, then clearly his focus in on that. Of course none of that may pan out but I think given his age, he wants out. He only cashes out in a sale. So to uplist puts him in the same spot where he holds hundreds of millions of shares and no way to cash out on Nasdaq.
Nasrat stopped over promising after sequestOx. Hes been super careful with his words each call. But two times in the past year his wording has been different. One was last November's call when he discussed Vyvanse (which had not yet been approved) but was approved the following week. The other is how he stated that the M&A was an option "and it looks like it is". He would not have risked saying that if something was in play. Things take time. But also remember, he only told us about hiring a firm after he had done it and it was already in play. I truly think we are much further along than most on this board think.
My one caveat is I think the sale price is much lower than most. I think the number will be in the $1.25, maybe $1.50 amount. He wants out and will take less to be done. But that's also more than double and possible triple current price.
This stock is very thinly traded. These volatile days are expected.
These are my opinions so do what you feel is best.
Nasrat stopped over promising after sequestOx. Hes been super careful with his words each call. But two times in the past year his wording has been different. One was last November's call when he discussed Vyvanse (which had not yet been approved) but was approved the following week. The other is how he stated that the M&A was an option "and it looks like it is". He would not have risked saying that if something was in play. Things take time. But also remember, he only told us about hiring a firm after he had done it and it was already in play. I truly think we are much further along than most on this board think.
My one caveat is I think the sale price is much lower than most. I think the number will be in the $1.25, maybe $1.50 amount. He wants out and will take less to be done. But that's also more than double and possible triple current price.
This stock is very thinly traded. These volatile days are expected.
These are my opinions so do what you feel is best.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
